Indication

Hyperphagia in Prader-Willi syndrome

Hyperphagia in Prader-Willi syndrome is a severe, hallmark neurobehavioral manifestation of a rare neurodevelopmental genetic disorder resulting from the loss of paternally expressed genes in chromosome region 15q11.2–q13. Read more about Hyperphagia in Prader-Willi syndrome

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Hyperphagia in Prader-Willi syndrome therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Hyperphagia in Prader-Willi syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hyperphagia in Prader-Willi syndrome.

Hyperphagia in Prader-Willi syndrome is a severe, hallmark neurobehavioral manifestation of a rare neurodevelopmental genetic disorder resulting from the loss of paternally expressed genes in chromosome region 15q11.2–q13.

It primarily affects the neuroendocrine and metabolic systems across pediatric and adult populations, emerging typically after an initial infantile phase of hypotonia and poor feeding.

Pathophysiologically driven by hypothalamic dysfunction—including disrupted signaling pathways regulating satiety and prolonged elevations in orexigenic hormones such as ghrelin—the condition is characterized by an insatiable hunger, profound lack of normal fullness, persistent food preoccupation, and compulsive food-seeking behaviors.

Without external environmental restrictions, this unrelenting drive to eat leads to rapid-onset hyperphagic obesity and life-threatening metabolic and cardiopulmonary complications.

Personalize your experience

Follow Hyperphagia in Prader-Willi syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it